Gilead Increases Investment In Arcus; Firms Abandon Chemo-Free Combo Study

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

With a $320m equity investment, Gilead will now own 33% of partner Arcus, which it said reinforces its optimism around the anti-TIGIT class for oncology.

Gilead HQ
Gilead increases its investment in Arcus and the anti-TIGIT mechanism • Source: Shutterstock

The latest event in the nearly four-year collaboration between Gilead Sciences, Inc. and Arcus Biosciences, Inc. saw Gilead increase its equity stake in its partner to approximately 33% in a transaction that Arcus said would give it financial runway into 2027. The two companies also announced that they are ending enrollment in a chemotherapy-free lung cancer trial to focus on other Phase III studies, while Arcus said it will conduct Phase III development of CD73 inhibitor quemliclustat in pancreatic cancer on its own.

Key Takeaways

  • Gilead increases its stake in Arcus, by paying $320m at a 37% premium to reach 33% equity in its partner.

Gilead announced after market close on 29 January that it will make a $320m equity investment in Arcus, increasing its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.